FLORA-5/GOG3035: Chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] vs chemotherapy (paclitaxel-carboplatin-placebo [PCP]) as front-line treatment in patients with advanced epithelial ovarian cancer (EOC)-Phase III, double blind, placebo controlled, global, multinational study
Publication
, Conference
Barroilhet, LM; Lim, MC; Gupta, S; Jada, SR; Lee, J-Y; Gilbert, L; Edraki, B; Cosgrove, C; Barlin, JN; Provencher, DM; Rob, L; Tewari, D ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
2023
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2023
Volume
41
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Barroilhet, L. M., Lim, M. C., Gupta, S., Jada, S. R., Lee, J.-Y., Gilbert, L., … Secord, A. A. (2023). FLORA-5/GOG3035: Chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] vs chemotherapy (paclitaxel-carboplatin-placebo [PCP]) as front-line treatment in patients with advanced epithelial ovarian cancer (EOC)-Phase III, double blind, placebo controlled, global, multinational study. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).
Barroilhet, Lisa Marie, Myong Cheol Lim, Sunil Gupta, Srinivas Rao Jada, Jung-Yun Lee, Lucy Gilbert, Babak Edraki, et al. “FLORA-5/GOG3035: Chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] vs chemotherapy (paclitaxel-carboplatin-placebo [PCP]) as front-line treatment in patients with advanced epithelial ovarian cancer (EOC)-Phase III, double blind, placebo controlled, global, multinational study.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.
Barroilhet LM, Lim MC, Gupta S, Jada SR, Lee J-Y, Gilbert L, et al. FLORA-5/GOG3035: Chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] vs chemotherapy (paclitaxel-carboplatin-placebo [PCP]) as front-line treatment in patients with advanced epithelial ovarian cancer (EOC)-Phase III, double blind, placebo controlled, global, multinational study. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.
Barroilhet, Lisa Marie, et al. “FLORA-5/GOG3035: Chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] vs chemotherapy (paclitaxel-carboplatin-placebo [PCP]) as front-line treatment in patients with advanced epithelial ovarian cancer (EOC)-Phase III, double blind, placebo controlled, global, multinational study.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.
Barroilhet LM, Lim MC, Gupta S, Jada SR, Lee J-Y, Gilbert L, Edraki B, Cosgrove C, Barlin JN, Provencher DM, Rob L, Tewari D, O’Malley DM, Secord AA. FLORA-5/GOG3035: Chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] vs chemotherapy (paclitaxel-carboplatin-placebo [PCP]) as front-line treatment in patients with advanced epithelial ovarian cancer (EOC)-Phase III, double blind, placebo controlled, global, multinational study. JOURNAL OF CLINICAL ONCOLOGY. 2023.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2023
Volume
41
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences